Logo 400x400.jpg

Madrigal is a public, clinical-stage biopharmaceutical company pursuing novel therapeutics for the treatment of liver disease.  Madrigal’s lead program, resmetirom, is in ongoing Phase 3 studies and has the potential to be first-to-market for the treatment of non-alcoholic steatohepatitis (NASH).


Madrigal’s most advanced clinical candidate, resmetirom, is an oral, liver-directed, thyroid hormone receptor beta (THR-β) selective agonist designed specifically to treat the underlying causes of NASH, while lowering multiple atherogenic lipids. 

  • Twitter
  • LinkedIn
  • YouTube

Contact Information

Steven Dzierba, PharmD MS BCPS FASHP

Field Director - West, Medical Affairs

817-201-3612  sdzierba@madrigalpharma.com

  • LinkedIn

Available throughout regular conference hours